Clearmind Medicine Inc. — Form 20-F summary
Reporting period: Fiscal year ended October 31, 2022; this is an annual report, not a standalone 2022 fourth-quarter report. The company reports in Canadian dollars (CAD) under IFRS. Clearmind is a preclinical psychedelic-drug developer focused primarily on MEAI for alcohol use disorder (AUD) and other indications. It had no approved products and had generated no product-sales revenue.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | CAD 4.205 million | CAD 0.646 million |
| General and administrative expense | CAD 4.327 million | CAD 3.030 million |
| Operating loss | CAD 8.533 million | CAD 3.676 million |
| Net loss | CAD 9.411 million | CAD 3.720 million |
| Cash used in operating activities | CAD 5.084 million | CAD 2.835 million |
| Cash and cash equivalents at year-end | CAD 0.176 million | CAD 4.599 million |
| Working capital | Negative CAD 2.044 million | Positive CAD 4.563 million |
FY2022 operating cash outflow rose 79%; R&D expense increased 550% and G&A expense increased 43%. The filing reports no meaningful operating margin because the company had no revenue. Net loss included CAD 0.421 million of unrealized losses on a Medigus investment and CAD 0.397 million of expense from a derivative liability. Share-based compensation was CAD 1.648 million.
At October 31, 2022, total assets were CAD 1.128 million and total liabilities were CAD 2.638 million; shareholders’ equity was negative CAD 1.510 million. Current liabilities included CAD 1.907 million of accounts payable and accrued liabilities, CAD 0.282 million due to related parties, a CAD 0.397 million derivative liability and CAD 0.052 million of lease liability. No conventional borrowings or debt securities are reported. Current assets included a CAD 0.264 million short-term investment in Medigus; its value had fallen by CAD 0.421 million during the year.
Material developments and outlook
- The company completed preclinical and IND-enabling studies and said it intended to submit an IND request and begin a Phase I/IIa MEAI study in Q1 2023. These were plans, not completed milestones. The FDA had discussed a possible hybrid study design involving healthy volunteers and AUD patients but had not approved it.
- Management expects substantial continuing losses and R&D spending, and says significant additional financing will be required. The audited statements include a going-concern warning: accumulated deficit was CAD 13.850 million, operating cash outflow was CAD 5.084 million, and negative working capital was CAD 2.044 million at year-end.
- After year-end, the company completed a Nasdaq offering of 1,153,847 shares at US$6.50 each, raising US$7.5 million gross and CAD 8.861 million net. The offering closed November 17, 2022. Medigus was also entitled to additional shares and warrants under an amended agreement; the filing said these had not yet been issued as of its date.
- Preclinical evidence is not clinical proof of safety or efficacy. The filing describes adverse effects and animal deaths at higher MEAI doses, including deaths in a dog cardiovascular study and neurotoxicity and mortality in a single-dose study in fasted rats. Human trials had not begun.
- Material risks include clinical failure or delay, controlled-substance scheduling and compliance, reliance on third-party researchers and manufacturers, future financing and dilution, intellectual-property protection, competition, and potential limits on reimbursement and market acceptance.
- Management concluded disclosure controls were ineffective and identified material weaknesses, including inadequate segregation of duties, control documentation, access reviews, vendor-control assessment, and written procedures. Remediation was underway; the filing does not establish that the weaknesses had been resolved.
- Saturna Group resigned as auditor in January 2023 and Deloitte’s network firm was appointed. The filing reports no disagreements or reportable events associated with the change. The 2022 financial statements received an unmodified audit opinion, with a going-concern explanatory paragraph.
Most important facts for investors to verify
- Whether the planned IND submission and Phase I/IIa trial began, and what regulators require regarding trial design and MEAI’s controlled-substance status.
- Cash runway and current liquidity after the November 2022 offering, including subsequent spending, liabilities, and any further financing or dilution.
- Final issuance and terms of Medigus-related shares and warrants, and any potential joint ventures or related-party arrangements.
- Whether internal-control weaknesses have been remediated and whether later filings report effective controls.
- Full preclinical safety findings, including dose-related toxicities and animal deaths, and how these affect proposed human dosing and trial plans.
- Progress and ownership or licensing terms for the company’s patent portfolio and university research programs.